The Relationship between Duration of Treatment and Drug Side Effects on SGOT and SGPT Levels in Pulmonary Tuberculosis Patients during the Continuation Phase at RSUD Dr. H. Abdul Moeloek

Backrgound: Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Its treatment consists of two phases: the intensive phase, which includes rifampicin, isoniazid, pyrazinamide, and ethambutol, and the continuation phase, which consists of rifampicin and isoniazid. Long-term use of anti-tuberculosis drugs may cause various adverse effects, with hepatotoxicity being one of the most serious. Objective: This study aimed to determine the relationship between the duration of treatment and drug side effects on SGOT and SGPT levels in pulmonary tuberculosis patients during the continuation phase at RSUD Dr. H. Abdul Moeloek. Methods: This study employed a retrospective, observational, non-experimental cross-sectional design. Data were collected from the medical records of pulmonary tuberculosis patients treated between January and August 2025, with a total sample size of 120 patients. Data were analyzed using the Chi-square test. Results: The results showed a significant relationship between treatment duration and SGOT/SGPT levels p = 0.001 (p < 0.05). A significant relationship was also found between drug side effects and SGOT/SGPT levels p = 0.001 (p < 0.05). Conclusion: It can be concluded that patients receiving anti-tuberculosis treatment for more than four months are at a higher risk of elevated SGOT and SGPT levels. Furthermore, higher SGOT and SGPT levels are associated with a greater likelihood of experiencing severe drug side effects.